Physician profile
Scotty Dwayne Combs
NPI 1730317561
$2,742.72
in general payments reported to CMS, 2019-2025
24 companies · $539 in 2025
The $539 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $372 · 2023: $660 · 2024: $545 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $564.90 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.15 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $298.08 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $277.30 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $247.46 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $146.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.76 | 2021-2025 | |
| Amgen INC. | $99.96 | 2024-2025 | Tezspire, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.42 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.86 | 2021-2023 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $80.30 | 2022-2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $73.63 | 2021 | |
| Lilly USA, LLC | $64.43 | 2021 | |
| Exact Sciences Corporation | $49.00 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $42.90 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.55 | 2021-2024 | Vaxneuvance, Gardasil, Vaxelis |
| Gilead Sciences, INC. | $23.62 | 2021 | |
| Kyowa Kirin, INC. | $18.81 | 2025 | |
| Medtronic, INC. | $18.20 | 2023 | Minimed 780g |
| Sanofi Pasteur INC. | $16.61 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.28 | 2021 | |
| Dexcom, INC. | $14.77 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $14.20 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.25 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scotty Combs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.